BioCentury
ARTICLE | Clinical News

NovaBiotics' oral Lynovex improves outcomes in Phase II for CF

July 27, 2018 6:53 PM UTC

NovaBiotics Ltd. (Aberdeen, U.K.) said oral Lynovex cysteamine (formerly NM001) as an adjunct to standard of care (SOC) significantly improved health-related questionnaire scores and reduced respiratory symptom severity compared with SOC alone in the Phase II CARE CF 1 trial to treat cystic fibrosis in adults. The company hopes to start a Phase III trial of the dual mucoactive-antibacterial in 1H19.

NovaBiotics said the 89-patient, double-blind, international trial evaluated five Lynovex dose regimens for two weeks to determine the dose regimen and endpoints for Phase III testing...

BCIQ Company Profiles

NovaBiotics Ltd.